Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-808-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.37 million
Profitability
Miscellaneous
Employees363
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma Inc (NASDAQ:TBPH) posted its quarterly earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the Zacks' consensus estimate of ($1.22) by $0.50. The biopharmaceutical company earned $26.15 million during the quarter, compared to analyst estimates of $13.92 million. View Theravance Biopharma's Earnings History.
When is Theravance Biopharma's next earnings date?
What price target have analysts set for TBPH?
3 analysts have issued 1 year price targets for Theravance Biopharma's shares. Their predictions range from $38.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $49.33 in the next twelve months. This suggests a possible upside of 190.2% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.
What is the consensus analysts' recommendation for Theravance Biopharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019)
- 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)
Has Theravance Biopharma been receiving favorable news coverage?
Media headlines about TBPH stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Theravance Biopharma earned a news impact score of 1.8 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Theravance Biopharma.
Are investors shorting Theravance Biopharma?
Theravance Biopharma saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 3,300,000 shares, a drop of 7.0% from the August 30th total of 3,550,000 shares. Based on an average trading volume of 246,400 shares, the short-interest ratio is presently 13.4 days. Approximately 7.7% of the company's stock are sold short. View Theravance Biopharma's Current Options Chain.
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), United Therapeutics (UTHR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO), Allakos (ALLK), Reata Pharmaceuticals (RETA), Alkermes (ALKS), Global Blood Therapeutics (GBT) and Emergent Biosolutions (EBS).
What other stocks do shareholders of Theravance Biopharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Bausch Health Companies (BHC), Exelixis (EXEL), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), SCYNEXIS (SCYX), Johnson & Johnson (JNJ), Tetraphase Pharmaceuticals (TTPH), Verastem (VSTM), Merck & Co., Inc. (MRK) and Clovis Oncology (CLVS).
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 59)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
- Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
- Mr. Vijay Sabesan, Sr. VP of Technical Operations
Who are Theravance Biopharma's major shareholders?
Theravance Biopharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.01%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala and Sharathchandra S Hegde. View Institutional Ownership Trends for Theravance Biopharma.
Which institutional investors are buying Theravance Biopharma stock?
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $17.00.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $962.83 million and generates $60.37 million in revenue each year. The biopharmaceutical company earns $-215,520,000.00 in net income (profit) each year or ($3.99) on an earnings per share basis. Theravance Biopharma employs 363 workers across the globe.View Additional Information About Theravance Biopharma.
What is Theravance Biopharma's official website?
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
